Enhancing Therapeutic Efficacy and Reducing Cell Dosage in Stem Cell Transplantation Therapy for Ischemic Limb Diseases by Modifying the Cell Injection Site

Tissue Engineering. Part a
Jung-Youn ShinByung-Soo Kim

Abstract

In conventional stem cell transplantation therapies for ischemic limb diseases, stem cells are generally transplanted into the ischemic region (IR), and most of the transplanted cells undergo hypoxia-mediated cell death. Due to massive cell death, the therapeutic efficacy is reduced and a high dose of stem cells is necessitated for the therapies. In this study, we investigated whether the therapeutic efficacy can be improved and the cell dosage can be reduced in the therapy for limb ischemia simply by modifying the stem cell injection site to a site where cell engraftment is improved and blood vessel sprouting is efficiently stimulated. Human mesenchymal stem cells (hMSCs) cultured under hypoxic condition, which simulates cells transplanted to IR, underwent extensive cell death in vitro. Importantly, cell death was significantly attenuated when hMSCs adhered first under normoxic condition for 24 h and then were exposed to hypoxic condition, which simulates cells transplanted to the border zone (BZ) in the upper thigh and migrated to IR. hMSCs, at doses of 2 × 10(5) or 2 × 10(6) cells, were injected into the IR or BZ of 5-week-old female athymic mice after ischemic hindlimb induction. Compared with human mesenchymal stem cell (h...Continue Reading

References

Apr 29, 1998·Annual Review of Physiology·T L CreazzoM L Kirby
May 10, 2001·Journal of Molecular and Cellular Cardiology·M ZhangC E Murry
Oct 29, 2002·Journal of Clinical Pathology·P A J KrijnenH W M Niessen
Jul 17, 2003·The Journal of Clinical Investigation·Orit KolletTsvee Lapidot
May 5, 2005·Tissue Engineering·Eric M BreyLarry V McIntire
Feb 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Elliott HillDavid J Mooney
Feb 25, 2006·The Journal of Clinical Investigation·Hui JinJudy Varner
Nov 30, 2006·Cancer·Genevieve Gallagher, Donna L Forrest
Feb 24, 2007·Nature Reviews. Molecular Cell Biology·Andrea Page-McCawZena Werb
Jul 21, 2007·The Medical Clinics of North America·Allen P Burke, Renu Virmani
Nov 19, 2008·Fibrogenesis & Tissue Repair·Jana S Burchfield, Stefanie Dimmeler
Nov 4, 2009·Journal of Diabetes Science and Technology·Yoshinori OnukiDiane J Burgess
Oct 13, 2010·Biochemical and Biophysical Research Communications·Lucy Youngmin EunKi-Chul Hwang
Dec 31, 2011·Biotechnology Letters·Jung-Youn ShinByung-Soo Kim
May 9, 2012·Tissue Engineering. Part a·Suk Ho BhangByung-Soo Kim
Jun 27, 2012·Cytotherapy·Murali Krishna MamidiAnjan Kumar Das
Aug 1, 2012·Stem Cell Research & Therapy·Aaron Liew, Timothy O'Brien
Jan 15, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Suk Ho BhangByung-Soo Kim
Sep 10, 2014·Proceedings of the National Academy of Sciences of the United States of America·Yaqian LiYanan Du

❮ Previous
Next ❯

Citations

Mar 7, 2021·International Journal of Molecular Sciences·Rouven BerndtRené Rusch
Oct 19, 2017·ACS Applied Materials & Interfaces·Gun-Jae JeongByung-Soo Kim

❮ Previous
Next ❯

Methods Mentioned

BETA
genetic modification
protein assay
electrophoresis
X-ray

Software Mentioned

OriginPro

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.